VVOS Company Profile and Key Details

Q: Who are the executives of VVOS?

Mr. Todd HuntsmanCo-Founder & Senior Vice President of Product and TechnologyPatrick KircherSenior Vice President of Sales & MarketingMr. R. Kirk HuntsmanCo-Founder, Chairman & Chief Executive OfficerMr. Bradford K. AmmanChief Financial Officer, Treasurer & Sec.Ms. Ruth HembreeSenior Vice President of Practice ServicesMr. Nicholas M. DeGennaroSenior Vice President of Medical DivisionMs. Susan McCulloughCo-Founder, Executive Vice President & Chief Experience OfficerPatrick KercherSenior Vice President of Sales & MarketingMr. Patrick KircherExecutive Vice President of Sales & MarketingMs. Julie GannonSenior Vice President of Product, Sales & MarketingMs. RaeAnn ByrnesCo-Founder and Senior Vice President of Events & Clinical Advisory ServicesMs. Stephanie HuebnerSenior Vice President of DSO Operations

NASDAQ : VVOS

Vivos Therapeutics

$0.42

-0.0124-2.87%

At Close 4:00 PM

68.47

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Vivos Therapeutics, Inc. (VVOS) stock declined over -2.87%, trading at $0.42 on NASDAQ, down from the previous close of $0.43. The stock opened at $0.43, fluctuating between $0.41 and $0.43 in the recent session.

Stock Snapshot

0.432

Prev. Close

2.47M

Market Cap

0.4125

Day Low

-0.2

P/E Ratio

-2.14

EPS (TTM)

-6.95

Cash Flow per Share

0.43

Open

5.89M

Number of Shares

0.43

Day High

54.21%

Free Float in %

0.22

Book Value

171.48K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	0.45	0.47	0.41	0.42	171.72K
Jul 10, 2026	0.46	0.46	0.43	0.43	172.31K
Jul 09, 2026	0.46	0.48	0.44	0.47	88.14K
Jul 08, 2026	0.46	0.48	0.45	0.48	139.28K
Jul 07, 2026	0.48	0.48	0.43	0.48	134.17K
Jul 06, 2026	0.47	0.48	0.45	0.48	105.09K
Jul 02, 2026	0.48	0.51	0.45	0.45	399.26K
Jul 01, 2026	0.47	0.53	0.46	0.50	443.71K
Jun 30, 2026	0.54	0.55	0.41	0.45	13.1M
Jun 29, 2026	0.47	0.50	0.45	0.49	151.57K
Jun 26, 2026	0.43	0.46	0.43	0.45	104.85K
Jun 25, 2026	0.45	0.46	0.42	0.43	155.12K
Jun 24, 2026	0.48	0.48	0.44	0.44	261.03K
Jun 23, 2026	0.38	0.47	0.38	0.47	974.97K
Jun 22, 2026	0.49	0.50	0.40	0.40	756.65K
Jun 18, 2026	0.52	0.52	0.45	0.50	499.47K
Jun 17, 2026	0.53	0.57	0.49	0.51	724.49K
Jun 16, 2026	0.57	0.58	0.52	0.54	282.92K
Jun 15, 2026	0.56	0.58	0.52	0.58	408.88K
Jun 12, 2026	0.58	0.62	0.56	0.57	279.42K

Contact Details

Littleton, CO 80120

United States

https://www.vivos.com 866 908 4867

About Company

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Stock Peers

ISRG

0.34+0.08%

Intuitive Surgical, Inc.$407.12 SWAV

-0.08-0.02%

ShockWave Medical, Inc.$334.75 UFPT

0.34+0.14%

UFP Technologies, Inc.$237.25 ALGN

1.14+0.64%

Align Technology, Inc.$180.59 MASI

Masimo Corporation$179.95 PODD

0.78+0.48%

Insulet Corp.$162.06 IRTC

2.55+2.20%

iRhythm Technologies, Inc.$118.68 IRMD

0.49+0.50%

IRadimed Corporation$97.69 ESTA

-0.13-0.15%

Establishment Labs Holdings Inc.$87.90 LIVN

0.42+0.51%

LivaNova PLC$82.98

Company Overview

Vivos Therapeutics, Inc. (NASDAQ:VVOS) closed at $0.42 USD, losing -$0.01 (-2.87%) from the previous close of $0.43. The stock is currently mid-range between its 52-week high and low $0.38 and $7.40. With a market capitalization of about $2.47 million, Vivos Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~6.12). Key stats such as the average daily volume over the past year has been around 1.71 million shares, volume is running light vs its 52-week average. Headquartered in Littleton, CO, Vivos Therapeutics, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO R. Kirk Huntsman, the company employs approximately 268 people and listed since December 11, 2020. Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -7.97%, SMA50 -21.71%, SMA200 -51.89%). The stock’s 14-day RSI is 34.7 (weak momentum), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -81.76% below its high and over 1.86% above its low. Average 10-day trading volume of 135.12 thousand shares is below the 3-month average of 1.71 million, indicating normal recent market interest.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Frequently Asked Questions

What is the current Vivos Therapeutics, Inc. (VVOS) stock price?

Vivos Therapeutics, Inc. (NASDAQ: VVOS) stock price is $0.42 in the last trading session. During the trading session, VVOS stock reached the peak price of $0.43 while $0.41 was the lowest point it dropped to. The percentage change in VVOS stock occurred in the recent session was -2.87% while the dollar amount for the price change in VVOS stock was - $0.01.

VVOS's industry and sector of operation?

The NASDAQ listed VVOS is part of Medical - Devices industry that operates in the broader Healthcare sector. Vivos Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VVOS?

Mr. Todd Huntsman
Co-Founder & Senior Vice President of Product and Technology
Patrick Kircher
Senior Vice President of Sales & Marketing
Mr. R. Kirk Huntsman
Co-Founder, Chairman & Chief Executive Officer
Mr. Bradford K. Amman
Chief Financial Officer, Treasurer & Sec.
Ms. Ruth Hembree
Senior Vice President of Practice Services
Mr. Nicholas M. DeGennaro
Senior Vice President of Medical Division
Ms. Susan McCullough
Co-Founder, Executive Vice President & Chief Experience Officer
Patrick Kercher
Senior Vice President of Sales & Marketing
Mr. Patrick Kircher
Executive Vice President of Sales & Marketing
Ms. Julie Gannon
Senior Vice President of Product, Sales & Marketing
Ms. RaeAnn Byrnes
Co-Founder and Senior Vice President of Events & Clinical Advisory Services
Ms. Stephanie Huebner
Senior Vice President of DSO Operations

How VVOS did perform over past 52-week?

VVOS's closing price is 9.56% higher than its 52-week low of $0.38 where as its distance from 52-week high of $7.40 is -94.33%.

How many employees does VVOS have?

Number of VVOS employees currently stands at 270.

Link for VVOS official website?

Official Website of VVOS is: https://www.vivos.com

How do I contact VVOS?

VVOS could be contacted at phone 866 908 4867 and can also be accessed through its website. VVOS operates from 7921 Southpark Plaza, Littleton, CO 80120, United States.

How many shares of VVOS are traded daily?

VVOS stock volume for the day was 171.48K shares. The average number of VVOS shares traded daily for last 3 months was 1.71M.

What is the market cap of VVOS currently?

The market value of VVOS currently stands at $2.47M with its latest stock price at $0.42 and 5.89M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Stock Snapshot

0.432

Prev. Close

2.47M

Market Cap

0.4125

Day Low

-0.2

P/E Ratio

-2.14

EPS (TTM)

-6.95

Cash Flow per Share

0.43

Open

5.89M

Number of Shares

0.43

Day High

54.21%

Free Float in %

0.22

Book Value

171.48K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	0.45	0.47	0.41	0.42	171.72K
Jul 10, 2026	0.46	0.46	0.43	0.43	172.31K
Jul 09, 2026	0.46	0.48	0.44	0.47	88.14K
Jul 08, 2026	0.46	0.48	0.45	0.48	139.28K
Jul 07, 2026	0.48	0.48	0.43	0.48	134.17K
Jul 06, 2026	0.47	0.48	0.45	0.48	105.09K
Jul 02, 2026	0.48	0.51	0.45	0.45	399.26K
Jul 01, 2026	0.47	0.53	0.46	0.50	443.71K
Jun 30, 2026	0.54	0.55	0.41	0.45	13.1M
Jun 29, 2026	0.47	0.50	0.45	0.49	151.57K
Jun 26, 2026	0.43	0.46	0.43	0.45	104.85K
Jun 25, 2026	0.45	0.46	0.42	0.43	155.12K
Jun 24, 2026	0.48	0.48	0.44	0.44	261.03K
Jun 23, 2026	0.38	0.47	0.38	0.47	974.97K
Jun 22, 2026	0.49	0.50	0.40	0.40	756.65K
Jun 18, 2026	0.52	0.52	0.45	0.50	499.47K
Jun 17, 2026	0.53	0.57	0.49	0.51	724.49K
Jun 16, 2026	0.57	0.58	0.52	0.54	282.92K
Jun 15, 2026	0.56	0.58	0.52	0.58	408.88K
Jun 12, 2026	0.58	0.62	0.56	0.57	279.42K

Contact Details

Littleton, CO 80120

United States

https://www.vivos.com 866 908 4867

About Company

Stock Peers

ISRG

0.34+0.08%

Intuitive Surgical, Inc.$407.12 SWAV

-0.08-0.02%

ShockWave Medical, Inc.$334.75 UFPT

0.34+0.14%

UFP Technologies, Inc.$237.25 ALGN

1.14+0.64%

Align Technology, Inc.$180.59 MASI

Masimo Corporation$179.95 PODD

0.78+0.48%

Insulet Corp.$162.06 IRTC

2.55+2.20%

iRhythm Technologies, Inc.$118.68 IRMD

0.49+0.50%

IRadimed Corporation$97.69 ESTA

-0.13-0.15%

Establishment Labs Holdings Inc.$87.90 LIVN

0.42+0.51%

LivaNova PLC$82.98

Company Overview

Technical Performance

Valuation Metrics

Vivos Therapeutics, Inc. trades at a P/E ratio of -0.18, slightly below the S&P 500 average, with a price-to-sales ratio of 0.13 and a price-to-book ratio of -5.34 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.13, also above market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Vivos Therapeutics, Inc. generated EPS of -$1.97 over the past year. Five-year average earnings growth is 32.77%. The latest quarter delivered EPS of -$0.52. The next quarter is forecast at -$0.48. Next year's EPS is expected at $59.76. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $2.50. The high target offers 1566.67% upside. The low target suggests 495.24% downside. The mean target is $4.77. This offers 1035.71% upside. Vivos Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 20, 2026, missed forecasts by 44.44%. The prior quarter beat by 17.17%. Over the last six quarters, Apple has recorded several small beats. These include -34.88% in March 31, 2025.

Shareholding & Insider Activity

Vivos Therapeutics, Inc. has 7.50 million shares outstanding. The public float is 5.43 million shares, elevated short interest at 2.81% of float. This equals 194.29 thousand shares. The short ratio is 1.11 days. Institutional investors hold 18.94% of the float. Insiders own 25.72%. Skaff Michael C holds 429.96 thousand shares, Huntsman Ronald Kirk has 86.52 thousand shares and Amman Bradford K. has 2.00 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Vivos Therapeutics generated $13.80M in revenue, or $11.32 per share. Gross margin was 55.43%, operating margin -125.32%, and net profit margin -98.42%. Returns are negative, with ROA at -126.59% and ROE at -3304.87%.
On valuation metrics, Vivos Therapeutics trades at a P/E of -0.18, P/S of 0.13 and P/B of -5.34. Liquidity is tight, with a current ratio of 0.27 and quick ratio of 0.27. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -58.90 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -10.78, supported by a cash flow-to-debt ratio of -1.42.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Vivos Therapeutics posted revenue of $13.80M, down slightly from $16.02M in the prior quarter. Gross profit was $7.65M (margin 55.43%). Operating income was - $17.30M (margin -125.3%). Net income was- $13.58M (EPS - $11.14).
The company ended the quarter with $1.64M in cash and short-term investments, a total debt of $2.00M, and net debt of $352.00K. Total assets were $10.73M, with equity of $411.00K. Financials further reflected weakness, with operating cash flow of - $11.95M, free cash flow of - $12.80M, and capital expenditures of - $853.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Vivos Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -16.59%, with price expected at $0.35 by July 27, 2026, within a range of $0.25 to $0.45 3-Month Outlook: Projected fall of -64.25%, reaching $0.15 by October 08, 2026, with a range of $0.05 to $0.25. 1-Year Outlook: Projected loss of -90.47%, with price at $0.04 by July 13, 2027, within a range of $0.00 to $0.52.

Key Takeaways

Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares are flat -2.96% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Vivos Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.18. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.03, suggesting 1098.76% upside. Our AI forecast model points to short-term weakness (-16.59% over two weeks), a medium-term fall (-64.25% over three months), and a longer-term loss (-90.47% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Vivos Therapeutics, Inc. (VVOS) stock price?

VVOS's industry and sector of operation?

Who are the executives of VVOS?

How VVOS did perform over past 52-week?

VVOS's closing price is 9.56% higher than its 52-week low of $0.38 where as its distance from 52-week high of $7.40 is -94.33%.

How many employees does VVOS have?

Number of VVOS employees currently stands at 270.

Link for VVOS official website?

Official Website of VVOS is: https://www.vivos.com

How do I contact VVOS?

VVOS could be contacted at phone 866 908 4867 and can also be accessed through its website. VVOS operates from 7921 Southpark Plaza, Littleton, CO 80120, United States.

How many shares of VVOS are traded daily?

VVOS stock volume for the day was 171.48K shares. The average number of VVOS shares traded daily for last 3 months was 1.71M.

What is the market cap of VVOS currently?

The market value of VVOS currently stands at $2.47M with its latest stock price at $0.42 and 5.89M of its shares outstanding.

Employees	270
Beta	6.12
Sales or Revenue	$13.80M
5Y Sales Change%	0.379%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

Employees	270
Beta	6.12
Sales or Revenue	$13.80M
5Y Sales Change%	0.379%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

VVOS Company Profile and Key Details

Vivos Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Dividend & Fair Value

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Valuation Metrics

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights